Delfi Liquid Biopsy Shows Promise for Reducing Lung Cancer Deaths
Retrieved on:
Friday, August 20, 2021
Nature, Population, Degenerative disease, USPSTF, SCLC, PALO, Death, Cancer, Adoption, Prognosis, Liquid biopsy, DNA, Lung cancer, Disease, COPD, Machine learning, Cough, Nature Communications, Lung cancer screening, Multimedia, LUCAS, Mortality, NSCLC, Delfi, Algorithm, CT, View, MD, Medical imaging, Pharmaceutical industry
Delfi Diagnostics Inc.'s lung cancer screening technology, which uses advanced machine learning algorithms to analyze genome-wide cell-free DNA fragmentation profiles, was able to detect approximately 90% of cancer cases in a group of nearly 800 individuals who underwent lung cancer screening with a low-dose CT (LDCT) scan.
Key Points:
- Delfi Diagnostics Inc.'s lung cancer screening technology, which uses advanced machine learning algorithms to analyze genome-wide cell-free DNA fragmentation profiles, was able to detect approximately 90% of cancer cases in a group of nearly 800 individuals who underwent lung cancer screening with a low-dose CT (LDCT) scan.
- Lung cancer is the leading cause of cancer deaths, with the vast majority of lung cancers detected at late stages when prognosis is poor.
- "These results suggest that the Delfi lung cancer screening technology could help reduce lung cancer deaths by offering a convenient, high-performing test to people who are USPSTF eligible," said Delfi CMO Peter B. Bach, MD.
- Delfi is developing a new class of liquid biopsy for early detection based on altered genome-wide fragmentation profiles, also known as "fragmentomes," a result of disordered packaging of DNA in cancer cells.